<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/168"/><api:result><api:object category="publication" id="168" last-affected-when="2024-03-17T09:27:59.62+00:00" last-modified-when="2024-03-17T09:27:59.62+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/168" created-when="2010-05-17T13:46:12.527+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2001-12-24</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1491651" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1046/j.1365-2125.1999.00884.x" last-modified-when="2023-09-23T02:28:28.51+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>&lt;jats:p&gt;Therapeutic drug monitoring is not routinely used for cytotoxic agents. There are several reasons, but one major drawback is the lack of established therapeutic concentration ranges. Combination chemotherapy makes the establishment of therapeutic ranges for individual drugs difficult, the concentration‐effect relationship for a single drug may not be the same as that when the drug is used in a drug combination. Pharmacokinetic optimization protocols for many classes of cytotoxic compounds exist in specialized centres, and some of these protocols are now part of large multicentre trials. Nonetheless, methotrexate is the only agent which is routinely monitored in most treatment centres. An additional factor, especially in antimetabolite therapy, is the existence of pharmacogenetic enzymes which play a major role in drug metabolism. Monitoring of therapy could include assay of phenotypic enzyme activities or genotype in addition to, or instead of, the more traditional measurement of parent drug or drug metabolites. The cytotoxic activities of mercaptopurine and fluorouracil are regulated by thiopurine methyltransferase (TPMT) and dihydropyrimidine dehydrogenase (DPD), respectively. Lack of TPMT functional activity produces life‐threatening mercaptopurine myelotoxicity. Very low DPD activity reduces fluorouracil breakdown producing severe cytotoxicity. These pharmacogenetic enzymes can influence the bioavailability, pharmacokinetics, toxicity and efficacy of their substrate drugs.&lt;/jats:p&gt;</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2083" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2083"/></api:links><api:last-name>Lennard</api:last-name><api:initials></api:initials></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1046/j.1365-2125.1999.00884.x</api:text><api:links><api:link type="doi" href="http://doi.org/10.1046/j.1365-2125.1999.00884.x"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1046/j.1365-2125.1999.00884.x"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1365-2125</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0306-5251</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Clinical Pharmacology</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>24</api:day><api:month>12</api:month><api:year>2001</api:year></api:date></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>131</api:begin-page><api:end-page>143</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wiley</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1046/j.1365-2125.1999.00884.x</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>11</api:day><api:month>9</api:month><api:year>2023</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Therapeutic drug monitoring of antimetabolic cytotoxic drugs</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>47</api:text></api:field></api:native></api:record><api:record format="native" id="94752" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033028272" last-modified-when="2023-11-22T06:25:51.067+00:00"><api:citation-count>76</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Therapeutic drug monitoring is not routinely used for cytotoxic agents. There are several reasons, but one major drawback is the lack of established therapeutic concentration ranges. Combination chemotherapy makes the establishment of therapeutic ranges for individual drugs difficult, the concentration-effect relationship for a single drug may not be the same as that when the drug is used in a drug combination. Pharmacokinetic optimization protocols for many classes of cytotoxic compounds exist in specialized centres, and some of these protocols are now part of large multicentre trials. Nonetheless, methotrexate is the only agent which is routinely monitored in most treatment centres. An additional factor, especially in antimetabolite therapy, is the existence of pharmacogenetic enzymes which play a major role in drug metabolism. Monitoring of therapy could include assay of phenotypic enzyme activities or genotype in addition to, or instead of, the more traditional measurement of parent drug or drug metabolites. The cytotoxic activities of mercaptopurine and fluorouracil are regulated by thiopurine methyltransferase (TPMT) and dihydropyrimidine dehydrogenase (DPD), respectively. Lack of TPMT functional activity produces life-threatening mercaptopurine myelotoxicity. Very low DPD activity reduces fluorouracil breakdown producing severe cytotoxicity. These pharmacogenetic enzymes can influence the bioavailability, pharmacokinetics, toxicity and efficacy of their substrate drugs.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2083" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2083"/></api:links><api:last-name>Lennard</api:last-name><api:initials>L</api:initials><api:first-names>L</api:first-names><api:separate-first-names><api:first-name>L</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">The University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="GB"><api:line type="organisation">Royal Hallamshire Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7004742950</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1046/j.1365-2125.1999.00884.x</api:text><api:links><api:link type="doi" href="http://doi.org/10.1046/j.1365-2125.1999.00884.x"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1046/j.1365-2125.1999.00884.x"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10190647</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0306-5251</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Clinical Pharmacology</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>131</api:begin-page><api:end-page>143</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>19</api:day><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Therapeutic drug monitoring of antimetabolic cytotoxic drugs</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>47</api:text></api:field></api:native></api:record><api:record format="native" id="168" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10190647" last-modified-when="2020-04-28T21:31:27.01+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Therapeutic drug monitoring is not routinely used for cytotoxic agents. There are several reasons, but one major drawback is the lack of established therapeutic concentration ranges. Combination chemotherapy makes the establishment of therapeutic ranges for individual drugs difficult, the concentration-effect relationship for a single drug may not be the same as that when the drug is used in a drug combination. Pharmacokinetic optimization protocols for many classes of cytotoxic compounds exist in specialized centres, and some of these protocols are now part of large multicentre trials. Nonetheless, methotrexate is the only agent which is routinely monitored in most treatment centres. An additional factor, especially in antimetabolite therapy, is the existence of pharmacogenetic enzymes which play a major role in drug metabolism. Monitoring of therapy could include assay of phenotypic enzyme activities or genotype in addition to, or instead of, the more traditional measurement of parent drug or drug metabolites. The cytotoxic activities of mercaptopurine and fluorouracil are regulated by thiopurine methyltransferase (TPMT) and dihydropyrimidine dehydrogenase (DPD), respectively. Lack of TPMT functional activity produces life-threatening mercaptopurine myelotoxicity. Very low DPD activity reduces fluorouracil breakdown producing severe cytotoxicity. These pharmacogenetic enzymes can influence the bioavailability, pharmacokinetics, toxicity and efficacy of their substrate drugs.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2083" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2083"/></api:links><api:last-name>Lennard</api:last-name><api:initials>L</api:initials><api:first-names>L</api:first-names><api:separate-first-names><api:first-name>L</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">University of Sheffield, Clinical Sciences Division (CSUH), Royal Hallamshire Hospital, UK.</api:line></api:address></api:addresses></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10190647</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1046/j.1365-2125.1999.00884.x</api:text><api:links><api:link type="doi" href="http://doi.org/10.1046/j.1365-2125.1999.00884.x"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1046/j.1365-2125.1999.00884.x"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pmc">PMC2014172</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0306-5251</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Br J Clin Pharmacol</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Antimetabolites, Antineoplastic</api:keyword><api:keyword scheme="mesh">Cytarabine</api:keyword><api:keyword scheme="mesh">Drug Monitoring</api:keyword><api:keyword scheme="mesh">Fluorouracil</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Mercaptopurine</api:keyword><api:keyword scheme="mesh">Methotrexate</api:keyword><api:keyword scheme="mesh">Neoplasms</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>131</api:begin-page><api:end-page>143</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>16</api:day><api:month>6</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Therapeutic drug monitoring of antimetabolic cytotoxic drugs.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>47</api:text></api:field></api:native></api:record><api:record format="native" id="858407" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10190647" last-modified-when="2022-03-02T00:08:26.783+00:00"><api:citation-count>37</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Therapeutic drug monitoring is not routinely used for cytotoxic agents. There are several reasons, but one major drawback is the lack of established therapeutic concentration ranges. Combination chemotherapy makes the establishment of therapeutic ranges for individual drugs difficult, the concentration-effect relationship for a single drug may not be the same as that when the drug is used in a drug combination. Pharmacokinetic optimization protocols for many classes of cytotoxic compounds exist in specialized centres, and some of these protocols are now part of large multicentre trials. Nonetheless, methotrexate is the only agent which is routinely monitored in most treatment centres. An additional factor, especially in antimetabolite therapy, is the existence of pharmacogenetic enzymes which play a major role in drug metabolism. Monitoring of therapy could include assay of phenotypic enzyme activities or genotype in addition to, or instead of, the more traditional measurement of parent drug or drug metabolites. The cytotoxic activities of mercaptopurine and fluorouracil are regulated by thiopurine methyltransferase (TPMT) and dihydropyrimidine dehydrogenase (DPD), respectively. Lack of TPMT functional activity produces life-threatening mercaptopurine myelotoxicity. Very low DPD activity reduces fluorouracil breakdown producing severe cytotoxicity. These pharmacogenetic enzymes can influence the bioavailability, pharmacokinetics, toxicity and efficacy of their substrate drugs.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">University of Sheffield, Clinical Sciences Division (CSUH), Royal Hallamshire Hospital, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2083" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2083"/></api:links><api:last-name>Lennard</api:last-name><api:initials>L</api:initials><api:first-names>L</api:first-names><api:separate-first-names><api:first-name>L</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1046/j.1365-2125.1999.00884.x</api:text><api:links><api:link type="doi" href="http://doi.org/10.1046/j.1365-2125.1999.00884.x"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1046/j.1365-2125.1999.00884.x"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1365-2125</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10190647</api:identifier><api:identifier scheme="pmc">PMC2014172</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0306-5251</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British journal of clinical pharmacology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Neoplasms</api:keyword><api:keyword scheme="mesh">Fluorouracil</api:keyword><api:keyword scheme="mesh">Methotrexate</api:keyword><api:keyword scheme="mesh">Cytarabine</api:keyword><api:keyword scheme="mesh">Antimetabolites, Antineoplastic</api:keyword><api:keyword scheme="mesh">Drug Monitoring</api:keyword><api:keyword scheme="mesh">Mercaptopurine</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>131</api:begin-page><api:end-page>143</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>6</api:day><api:month>4</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Therapeutic drug monitoring of antimetabolic cytotoxic drugs.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>review-article</api:item><api:item>Review</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>47</api:text></api:field></api:native></api:record><api:record format="native" id="2930563" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1029819239" last-modified-when="2024-03-17T09:27:59.637+00:00"><api:citation-count>67</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2083" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2083"/></api:links><api:last-name>Lennard</api:last-name><api:initials>L</api:initials><api:first-names>L</api:first-names><api:separate-first-names><api:first-name>L</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="GB"><api:line type="organisation">Royal Hallamshire Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01020201434.67</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1046/j.1365-2125.1999.00884.x</api:text><api:links><api:link type="doi" href="http://doi.org/10.1046/j.1365-2125.1999.00884.x"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1046/j.1365-2125.1999.00884.x"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10190647</api:identifier><api:identifier scheme="pmc">PMC2014172</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0306-5251</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Clinical Pharmacology</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">3214 Pharmacology and Pharmaceutical Sciences</api:keyword><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Orphan Drug</api:keyword><api:keyword scheme="rcdc">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="hrcs-rac">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="mesh">Antimetabolites, Antineoplastic</api:keyword><api:keyword scheme="mesh">Cytarabine</api:keyword><api:keyword scheme="mesh">Drug Monitoring</api:keyword><api:keyword scheme="mesh">Fluorouracil</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Mercaptopurine</api:keyword><api:keyword scheme="mesh">Methotrexate</api:keyword><api:keyword scheme="mesh">Neoplasms</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>24</api:day><api:month>12</api:month><api:year>2001</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Green OA</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>131</api:begin-page><api:end-page>143</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wiley</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>1.46</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Therapeutic drug monitoring of antimetabolic cytotoxic drugs</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>47</api:text></api:field></api:native></api:record><api:record format="native" id="239706" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000078676700002" last-modified-when="2024-03-14T05:50:42.453+00:00"><api:citation-count>59</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2083" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2083"/></api:links><api:last-name>Lennard</api:last-name><api:initials>L</api:initials><api:first-names>L</api:first-names><api:separate-first-names><api:first-name>L</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="researcherid">E-1131-2011</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000078676700002&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">168DU</api:identifier><api:identifier scheme="pubmed">10190647</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0306-5251</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRITISH JOURNAL OF CLINICAL PHARMACOLOGY</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>antimetabolites</api:keyword><api:keyword>cytosine arabinoside</api:keyword><api:keyword>cytotoxic drugs</api:keyword><api:keyword>fluorouracil</api:keyword><api:keyword>mercaptopurine</api:keyword><api:keyword>methotrexate</api:keyword><api:keyword>therapeutic drug monitoring</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>131</api:begin-page><api:end-page>143</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Therapeutic drug monitoring of antimetabolic cytotoxic drugs</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Review</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>47</api:text></api:field></api:native></api:record><api:record format="native" id="22189" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000078676700002" last-modified-when="2014-07-25T11:01:11.207+01:00"><api:citation-count>25</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="2083" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2083"/></api:links><api:last-name>Lennard</api:last-name><api:initials>L</api:initials><api:first-names>L</api:first-names><api:separate-first-names><api:first-name>L</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0306-5251</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>2</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRIT J CLIN PHARMACO</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>antimetabolites</api:keyword><api:keyword>cytosine arabinoside</api:keyword><api:keyword>cytotoxic drugs</api:keyword><api:keyword>fluorouracil</api:keyword><api:keyword>mercaptopurine</api:keyword><api:keyword>methotrexate</api:keyword><api:keyword>therapeutic drug monitoring</api:keyword><api:keyword>ACUTE LYMPHOBLASTIC-LEUKEMIA</api:keyword><api:keyword>PERFORMANCE LIQUID-CHROMATOGRAPHY</api:keyword><api:keyword>THIOPURINE METHYLTRANSFERASE ACTIVITY</api:keyword><api:keyword>DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY</api:keyword><api:keyword>FLUORESCENCE POLARIZATION IMMUNOASSAY</api:keyword><api:keyword>ACUTE LYMPHOCYTIC-LEUKEMIA</api:keyword><api:keyword>BLOOD MONONUCLEAR-CELLS</api:keyword><api:keyword>ACUTE MYELOID-LEUKEMIA</api:keyword><api:keyword>CYTOSINE-ARABINOSIDE</api:keyword><api:keyword>PLASMA-LEVELS</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>131</api:begin-page><api:end-page>143</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Therapeutic drug monitoring of antimetabolic cytotoxic drugs</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>47</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antimetabolites, Antineoplastic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cytarabine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Drug Monitoring</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Fluorouracil</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mercaptopurine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Methotrexate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Fluorouracil</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Methotrexate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cytarabine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antimetabolites, Antineoplastic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Drug Monitoring</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mercaptopurine</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3214 Pharmacology and Pharmaceutical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Orphan Drug</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antimetabolites, Antineoplastic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cytarabine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Drug Monitoring</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Fluorouracil</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mercaptopurine</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Methotrexate</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neoplasms</api:keyword><api:keyword origin="record-data" source="wos-lite">antimetabolites</api:keyword><api:keyword origin="record-data" source="wos-lite">cytosine arabinoside</api:keyword><api:keyword origin="record-data" source="wos-lite">cytotoxic drugs</api:keyword><api:keyword origin="record-data" source="wos-lite">fluorouracil</api:keyword><api:keyword origin="record-data" source="wos-lite">mercaptopurine</api:keyword><api:keyword origin="record-data" source="wos-lite">methotrexate</api:keyword><api:keyword origin="record-data" source="wos-lite">therapeutic drug monitoring</api:keyword><api:keyword origin="record-data" source="wos">antimetabolites</api:keyword><api:keyword origin="record-data" source="wos">cytosine arabinoside</api:keyword><api:keyword origin="record-data" source="wos">cytotoxic drugs</api:keyword><api:keyword origin="record-data" source="wos">fluorouracil</api:keyword><api:keyword origin="record-data" source="wos">mercaptopurine</api:keyword><api:keyword origin="record-data" source="wos">methotrexate</api:keyword><api:keyword origin="record-data" source="wos">therapeutic drug monitoring</api:keyword><api:keyword origin="record-data" source="wos">ACUTE LYMPHOBLASTIC-LEUKEMIA</api:keyword><api:keyword origin="record-data" source="wos">PERFORMANCE LIQUID-CHROMATOGRAPHY</api:keyword><api:keyword origin="record-data" source="wos">THIOPURINE METHYLTRANSFERASE ACTIVITY</api:keyword><api:keyword origin="record-data" source="wos">DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY</api:keyword><api:keyword origin="record-data" source="wos">FLUORESCENCE POLARIZATION IMMUNOASSAY</api:keyword><api:keyword origin="record-data" source="wos">ACUTE LYMPHOCYTIC-LEUKEMIA</api:keyword><api:keyword origin="record-data" source="wos">BLOOD MONONUCLEAR-CELLS</api:keyword><api:keyword origin="record-data" source="wos">ACUTE MYELOID-LEUKEMIA</api:keyword><api:keyword origin="record-data" source="wos">CYTOSINE-ARABINOSIDE</api:keyword><api:keyword origin="record-data" source="wos">PLASMA-LEVELS</api:keyword><api:keyword scheme="for" origin="issn-inferred">1115 Pharmacology and Pharmaceutical Sciences</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Pharmacology &amp; Pharmacy</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3214 Pharmacology and pharmaceutical sciences</api:keyword></api:keywords></api:all-labels><api:journal issn="0306-5251" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972939" title="British Journal of Clinical Pharmacology"><api:records><api:record source-name="summary"><api:title>British Journal of Clinical Pharmacology</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/168/relationships"/></api:object></api:result></api:response>